keyword
MENU ▼
Read by QxMD icon Read
search

melanoma remission

keyword
https://www.readbyqxmd.com/read/27917631/-15-years-experience-with-biological-therapy-of-inflammatory-rheumatic-diseases-in-czech-national-register-attra
#1
Karel Pavelka, Liliana Šedová, Karel Hejduk, Ladislav Dušek
The publication is summarizing application of biological DMARDs in autoimmune inflammatory rheumatic diseases.Up to now conventional therapy, which for example in rheumatoid arthritis was application of methotrexate (MTx) in combination with glucocorticoids, was effective, but the remission as a target was achieved in small proportion of patients and also there was little effect on structural progression of diseases. Biological therapy was great advance because response was achieved in ¾ patients who failed MTx...
2016: Casopís Lékar̆ů C̆eských
https://www.readbyqxmd.com/read/27914118/blue-lymphangitis-of-the-breast-after-breast-cancer-case-report
#2
Alexandra Arfi, Alice Clavier, Jean F Honart, Samy Ammari, Zahira Merabet, Christine Mateus, Julia Arfi-Rouche
Carcinomatous lymphangitis accounts for 5% of all skin metastases, but blue lymphangitis of the breast has never been described. We report a case of blue lymphangitis of the breast in a patient 11 years after treatment for ipsilateral breast cancer that was in full remission. Breast examination and imaging showed no other abnormalities. Skin biopsy revealed a carcinomatous-pigmented infiltration corresponding to melanoma metastasis, which helped highlight a primitive right flank injury. This case report emphasizes that a full body exam should always be performed with unusual presentation of breast cancer and reiterates the indispensable place of histology before any diagnosis...
December 3, 2016: Breast Journal
https://www.readbyqxmd.com/read/27861332/systemic-vasculitis-associated-with-vemurafenib-treatment-case-report-and-literature-review
#3
Adrien Mirouse, Léa Savey, Fanny Domont, Cloé Comarmond, Stéphane Barete, Emmanuelle Plaisier, Philippe Rouvier, Patrice Cacoub, David Saadoun
RATIONALE: Vemurafenib, an inhibitor of mutated B-rapidly accelerated fibrosarcoma, is frequently used in the treatment of melanoma and Erdheim-Chester disease (ECD) patients. Inflammatory adverse effects have been increasingly reported after vemurafenib treatment. PATIENT CONCERNS AND DIAGNOSE: We report 6 cases of vemurafenib-associated vasculitis, of whom a personal case of a 75-year-old man with history of ECD who developed purpura and rapidly progressive pauci-immune glomerulonephritis during treatment with vemurafenib...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27797970/molecular-pathways-maintaining-mapk-inhibitor-sensitivity-by-targeting-nonmutational-tolerance
#4
Michael P Smith, Claudia Wellbrock
Targeting hyperactive MAPK signaling has proven to be an effective treatment for a variety of different cancers. Responses to the BRAF inhibitors vemurafenib and dabrafenib and the MEK inhibitors trametinib and cobimetinib are, however, transient, and complete remission is rarely observed; rather, outgrowth of resistant clones within progressed tumors appears inevitable. These resistant tumors display great heterogeneity, which poses a major challenge to any salvage therapy. Recent focus has, therefore, been on the early dynamics of inhibitor response during tumor regression...
October 19, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27757318/adoptively-transferred-natural-killer-cells-maintain-long-term-antitumor-activity-by-epigenetic-imprinting-and-cd4-t-cell-help
#5
Jing Ni, Oliver Hölsken, Matthias Miller, Quirin Hammer, Merlin Luetke-Eversloh, Chiara Romagnani, Adelheid Cerwenka
Natural killer (NK) cell infusions can induce remissions in subsets of patients with different types of cancer. The optimal strategies for NK cell activation prior to infusion are still under debate. There is recent evidence that NK cells can acquire long-term functional competence by preactivation with the cytokines IL-12/15/18. The mechanisms supporting the maintenance of long-term NK cell antitumor activity are incompletely under-stood. Here, we show that NK cells preactivated in vitro with IL-12/15/18, but not with IL-15 alone, maintained high antitumor activity even 1 mo after transfer into lymphopenic RAG-2(-/-)γc(-/-) mice...
2016: Oncoimmunology
https://www.readbyqxmd.com/read/27689735/baricitinib-in-patients-with-inadequate-response-or-intolerance-to-conventional-synthetic-dmards-results-from-the-ra-build-study
#6
Maxime Dougados, Désirée van der Heijde, Ying-Chou Chen, Maria Greenwald, Edit Drescher, Jiajun Liu, Scott Beattie, Sarah Witt, Inmaculada de la Torre, Carol Gaich, Terence Rooney, Douglas Schlichting, Stephanie de Bono, Paul Emery
BACKGROUND: Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. METHODS: In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and inadequate response or intolerance to ≥1 conventional synthetic DMARDs were randomly assigned 1:1:1 to placebo or baricitinib (2 or 4 mg) once daily, stratified by region and the presence of joint erosions. Endpoint measures included American College of Rheumatology 20% response (ACR20, primary endpoint), Disease Activity Score (DAS28) and Simplified Disease Activity Index (SDAI) score ≤3...
September 29, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27684455/durable-response-of-metastatic-squamous-cell-carcinoma-of-the-skin-to-ipilimumab-immunotherapy
#7
Fiona Day, Mahesh Kumar, Linda Fenton, Craig Gedye
A 72-year-old male patient was receiving second-line chemotherapy for metastatic squamous cell carcinoma of the skin (SCCS) when he was diagnosed with concurrent metastatic melanoma (BRAF mutant). Chemotherapy was ceased and he was treated with 4 cycles of ipilimumab immunotherapy. The patient experienced clinical benefit and durable remission in both malignancies and remains free of cancer progression 8 months after the last cycle of ipilimumab. Response of SCCS to ipilimumab has not been previously described, however this case and recent reports of pembrolizumab efficacy confirm the critical role of the immune system in SCCS pathogenesis and suggest further exploration of checkpoint immunotherapy for the treatment of this disease...
January 2017: Journal of Immunotherapy
https://www.readbyqxmd.com/read/27572939/gli-inhibitor-gant61-kills-melanoma-cells-and-acts-in-synergy-with-obatoclax
#8
Kateřina Vlčková, Jiri Réda, Lubica Ondrušová, Mohammad Krayem, Ghanem Ghanem, Jiri Vachtenheim
MEK kinase inhibitors (trametinib and selumetinib) or kinase inhibitors directed against mutated BRAF(V600E) (vemurafenib and dabrafenib) have initial encouraging effects in the treatment of melanoma but acquired resistance appears almost invariably after some months. Studies revealed mutually exclusive NRAS and BRAF activating mutations driving the MAPK/ERK pathway among human melanomas. Although combination therapy exerts significantly better antitumor cell efficacy, complete remission is rarely achieved...
September 2016: International Journal of Oncology
https://www.readbyqxmd.com/read/27534680/cases-of-remission-of-psychosis-following-resection-of-pheochromocytoma-or-paraganglioma
#9
James S Brown
The author previously proposed that schizophrenia has similar cytokine expression compared to melanoma, a neural crest cell tumor. One possible tumor model of schizophrenia includes anti-NMDA receptor encephalitis, a paraneoplastic syndrome. While examining the possible relationship of neural crest cell tumors to schizophrenia, the author found several case reports of psychosis resulting from pheochromocytomas and paragangliomas, types of neural crest cell tumors that secrete catecholamines. In most cases, surgical resection of the tumors resulted in remission of psychotic symptoms, and some remissions were associated with reduced levels of peripheral catecholamine levels...
October 2016: Schizophrenia Research
https://www.readbyqxmd.com/read/27533448/clinical-outcomes-in-metastatic-uveal-melanoma-treated-with-pd-1-and-pd-1l-antibodies
#10
Alain P Algazi, Katy K Tsai, Alexander N Shoushtari, Rodrigo R Munhoz, Zeynep Eroglu, Josep M Piulats, Patrick A Ott, Douglas B Johnson, Jimmy Hwang, Adil I Daud, Jeffrey A Sosman, Richard D Carvajal, Bartosz Chmielowski, Michael A Postow, Jeffrey S Weber, Ryan J Sullivan
BACKGROUND: Antibodies inhibiting the programmed death receptor 1 (PD-1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma. The efficacy and safety of PD-1 blockade in patients with uveal melanoma has not been well characterized. METHODS: Fifty-eight patients with stage IV uveal melanoma received PD-1 or PD-1 ligand (PD-L1) antibodies between 2009 and 2015 at 9 academic centers. Patients who were evaluable for response were eligible for the analysis...
August 17, 2016: Cancer
https://www.readbyqxmd.com/read/27484791/molecular-and-epigenetic-features-of-melanomas-and-tumor-immune-microenvironment-linked-to-durable-remission-to-ipilimumab-based-immunotherapy-in-metastatic-patients
#11
Teofila Seremet, Alexander Koch, Yanina Jansen, Max Schreuer, Sofie Wilgenhof, Véronique Del Marmol, Danielle Liènard, Kris Thielemans, Kelly Schats, Mark Kockx, Wim Van Criekinge, Pierre G Coulie, Tim De Meyer, Nicolas van Baren, Bart Neyns
BACKGROUND: Ipilimumab (Ipi) improves the survival of advanced melanoma patients with an incremental long-term benefit in 10-15 % of patients. A tumor signature that correlates with this survival benefit could help optimizing individualized treatment strategies. METHODS: Freshly frozen melanoma metastases were collected from patients treated with either Ipi alone (n: 7) or Ipi combined with a dendritic cell vaccine (TriMixDC-MEL) (n: 11). Samples were profiled by immunohistochemistry (IHC), whole transcriptome (RNA-seq) and methyl-DNA sequencing (MBD-seq)...
August 2, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/27461037/the-promise-of-molecularly-targeted-and-immunotherapy-for-advanced-melanoma
#12
REVIEW
Kim Margolin
Advanced melanoma, rarely diagnosed at the time of primary melanoma excision but most often occurring later via lymphatic or hematogenous dissemination, is the cause of death for approximately 10,000 people in the USA each year, with the rate of incidence and death increasing yearly. Its causes are multifactorial and depend in large part on solar ultraviolet damage to DNA as well as underlying genetic predisposition. Cutaneous melanoma is the most common, but other subsets of importance are mucosal and uveal primaries, with different biology and treatment considerations...
September 2016: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/27438388/-no-hair-loss-but-colitis-or-pneumonitis-unique-side-effects-of-immune-checkpoint-inhibitors-for-cancer
#13
T G Steenbruggen, M M van den Heuvel, C U Blank, J M van Dieren, J B A G Haanen, M Kok
Immunotherapy with checkpoint inhibitors is an effective strategy for several cancers. In some patients long-term remissions are seen. However, enhancement of the immune response can be accompanied by immune-related adverse events (irAEs). These patients often present with nonspecific symptoms. The most common irAEs are dermatitis, colitis, pneumonitis, hepatitis and endocrinopathies. IrAEs can occur in every organ, even simultaneously. Furthermore, irAEs can occur weeks or months after discontinuation of checkpoint inhibitors...
2016: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/27373242/immune-checkpoint-inhibitors-a-milestone-in-the-treatment-of-melanoma
#14
REVIEW
Sophia M Wilden, Berenice M Lang, Peter Mohr, Stephan Grabbe
It has been known for decades that the immune system is able to detect and destroy tumor cells. In the past, this knowledge - mostly acquired through animal experiments - could not be used to benefit our patients, because immuno-oncological therapeutic approaches in humans had constantly failed over recent decades. With the exception of adjuvant interferon therapy, none of these approaches had found its way into everyday clinical practice, and only very few patients were able to enjoy long-term survival associated with good quality of life...
July 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/27280688/curcumin-a-new-candidate-for-melanoma-therapy
#15
REVIEW
Hamed Mirzaei, Gholamreza Naseri, Ramin Rezaee, Mohsen Mohammadi, Zarrin Banikazemi, Hamid Reza Mirzaei, Hossein Salehi, Mostafa Peyvandi, John M Pawelek, Amirhossein Sahebkar
Melanoma remains among the most lethal cancers and, in spite of great attempts that have been made to increase the life span of patients with metastatic disease, durable and complete remissions are rare. Plants and plant extracts have long been used to treat a variety of human conditions; however, in many cases, effective doses of herbal remedies are associated with serious adverse effects. Curcumin is a natural polyphenol that shows a variety of pharmacological activities including anti-cancer effects, and only minimal adverse effects have been reported for this phytochemical...
October 15, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27270408/-molecular-and-immunohistochemical-diagnostics-in-melanoma
#16
B Schilling, K G Griewank
To provide appropriate therapy and follow-up to patients with malignant melanoma, proper diagnostics are of critical importance. Targeted therapy of advanced melanoma is based on the molecular genetic analyses of tumor tissue. In addition, sequencing of genes and other genetic approaches can provide insight into the origin of melanocytic tumors and can aid in distinguishing benign from malignant lesions. In this regard, spizoid neoplasms remain a challenging entity. Aside from genetic analyses of tumor tissue, immunohistochemistry remains an essential tool in melanoma diagnostics and TNM classification...
July 2016: Der Hautarzt; Zeitschrift Für Dermatologie, Venerologie, und Verwandte Gebiete
https://www.readbyqxmd.com/read/27269940/t-cell-therapy-using-interleukin-21-primed-cytotoxic-t-cell-lymphocytes-combined-with-cytotoxic-t-cell-lymphocyte-antigen-4-blockade-results-in-long-term-cell-persistence-and-durable-tumor-regression
#17
Aude G Chapuis, Ilana M Roberts, John A Thompson, Kim A Margolin, Shailender Bhatia, Sylvia M Lee, Heather L Sloan, Ivy P Lai, Erik A Farrar, Felecia Wagener, Kendall C Shibuya, Jianhong Cao, Jedd D Wolchok, Philip D Greenberg, Cassian Yee
PURPOSE: Peripheral blood-derived antigen-specific cytotoxic T cells (CTLs) provide a readily available source of effector cells that can be administered with minimal toxicity in an outpatient setting. In metastatic melanoma, this approach results in measurable albeit modest clinical responses in patients resistant to conventional therapy. We reasoned that concurrent cytotoxic T-cell lymphocyte antigen-4 (CTLA-4) checkpoint blockade might enhance the antitumor activity of adoptively transferred CTLs...
June 6, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27254075/rapid-remission-of-symptomatic-brain-metastases-in-melanoma-by-programmed-death-receptor-1-inhibition
#18
Nadine Lüttmann, Victoria Grätz, Ozan Haase, Thomas Eckey, Ewan A Langan, Detlef Zillikens, Patrick Terheyden
Although ∼40% of patients with metastatic melanoma develop brain metastases, the presence of brain metastases often precludes enrolment in clinical trials for advanced melanoma. However, the development of symptomatic brain metastases markedly increases mortality. The antiprogrammed-death-receptor-1 antibody pembrolizumab achieves extracranial metastases disease response rates of up to 50%. Here, we report the rapid and sustained response of symptomatic multifocal brain metastases in a melanoma ipilimumab-pretreated patient under pembrolizumab, combined with high-dose dexamethasone therapy during the induction phase of therapy...
October 2016: Melanoma Research
https://www.readbyqxmd.com/read/27242164/combined-il-21-primed-polyclonal-ctl-plus-ctla4-blockade-controls-refractory-metastatic-melanoma-in-a-patient
#19
Aude G Chapuis, Sylvia M Lee, John A Thompson, Ilana M Roberts, Kim A Margolin, Shailender Bhatia, Heather L Sloan, Ivy Lai, Felecia Wagener, Kendall Shibuya, Jianhong Cao, Jedd D Wolchok, Philip D Greenberg, Cassian Yee
Adoptive transfer of peripheral blood-derived, melanoma-reactive CD8(+) cytotoxic T lymphocytes (CTLs) alone is generally insufficient to eliminate bulky tumors. Similarly, monotherapy with anti-CTLA4 infrequently yields sustained remissions in patients with metastatic melanoma. We postulated that a bolus of enhanced IL-21-primed polyclonal antigen-specific CTL combined with CTLA4 blockade might boost antitumor efficacy. In this first-in-human case study, the combination successfully led to a durable complete remission (CR) in a patient whose disease was refractory to both monoclonal CTL and anti-CTLA4...
June 27, 2016: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/27179389/extended-endoscopic-endonasal-approach-to-clival-and-paraclival-tumors-indications-and-limits
#20
M Messerer, G Cossu, P Pasche, C Ikonomidis, C Simon, E Pralong, M George, M Levivier, R T Daniel
OBJECTIVE: To report our experience with the Extended endoscopic endonasal approach (EEEA) for clival and paraclival tumors. DESIGN: Retrospective analysis of a consecutive series of patients. RESULTS: Eleven patients were considered: 3 chordomas, 3 meningiomas, 3 metastatic lesions, one chondroma and one chondrosarcoma. Gross total resection (GTR) was achieved in all chordomas and in chondromas with patients free of disease at the last follow-up...
June 2016: Neuro-Chirurgie
keyword
keyword
11576
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"